Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

RPTX 12.10.2024

SERA-AI Powered Highlights
Drug:RP-6306 lunresertib
Drug:RP-3500 camonsertib
Diseases:platinum-resistant ovarian and endometrial cancers
Diseases:platinum-resistant ovarian and endometrial cancers
Date of Upcoming Event:2024-12-12
Name of Upcoming Event:Conference Call and Live Webcast
Full Press ReleaseSEC FilingsOur RPTX Tweets

About Gravity Analytica

Recent News

  • 01.09.2025 - Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
  • 12.12.2024 - MYTHIC Lunresertib and Camonsertib Clinical Data Update
  • 12.12.2024 - Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Recent Filings

  • 01.15.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
  • 01.10.2025 - EX-99.1 EX-99.1
  • 01.10.2025 - 8-K Current report

Event to be webcast live onThursday, December 12at4:30 p.m. ET

CAMBRIDGE, Mass.&MONTREAL--(BUSINESS WIRE)--Dec. 10, 2024--Repare Therapeutics Inc.(“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib in combination with camonsertib at the recommended Phase 2 dose in an expansion cohort in patients with platinum-resistant ovarian and endometrial cancers harboring CCNE1 amplification or FBXW7 or PPP2R1A mutations, onThursday, December 12, 2024at4:30 p.m. Eastern Time. Repare’s executive management team will be joined byBrian Slomovitz, M.D., Director of Gynecologic Oncology atMount Sinai Medical Center.

Conference Call and Webcast Details:

To access the call, please dial (646) 357-8785 (U.S.andCanada) or (800) 836-8184 (international) at least 10 minutes prior to the start time and ask to be joined to theRepare Therapeuticscall. A live video webcast and presentation materials will be available in the Investor section of the Company’s website athttps://ir.reparerx.com/news-and-events/events. A webcast replay will also be archived for at least 30 days.

AboutRepare Therapeutics Inc.

Repare Therapeuticsis a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx®platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known asRP-6306), a PKMYT1 inhibitor currently in Phase 1/2 clinical development; camonsertib (also known asRP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development;RP-1664, a Phase 1 PLK4 inhibitor;RP-3467, a Phase 1 Polθ ATPase inhibitor; as well as additional, undisclosed preclinical programs. For more information, please visitreparerx.comand follow @Reparerx on X (formerly Twitter) and LinkedIn.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241210360746/en/

Investor Relations & Media:Robin GarnerVice President and Head of Investor RelationsRepare Therapeutics Inc.investor@reparerx.com

Source:Repare Therapeutics Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com